Suicide Risk Assessment

• Serotonergic dysfunction as the primary neurochemical pathway: The serotonergic system originating from raphe nuclei projects widely throughout the prefrontal cortex, anterior cingulate, amygdala, and limbic regions central to mood, impulse control, and decision-making. Reduced cerebrospinal fluid (CSF) 5-hydroxyindoleacetic acid (5-HIAA), a serotonin metabolite, has been consistently found in individuals who die by suicide, particularly those with violent methods. This serotonergic hypofunction creates a biological substrate favoring impulsive aggression, reduced capacity for behavioral inhibition, and heightened negative affect—all core risk factors for suicidal behavior. Postmortem studies reveal altered serotonin transporter (SERT) binding and 5-HT1A receptor density in prefrontal regions of suicide completers, suggesting both acute state-dependent and trait-like abnormalities. This neurochemical basis explains the efficacy of serotonin reuptake inhibitors (SSRIs) in reducing suicidality across multiple psychiatric conditions, though the initial weeks of SSRI therapy paradoxically may increase suicidal ideation in some individuals (discussed below).

• Hypothalamic-pituitary-adrenal (HPA) axis hyperactivation and stress-response dysregulation: Individuals at risk for suicide demonstrate chronic hyperactivity of the HPA axis with elevated baseline cortisol, blunted cortisol response to dexamethasone suppression, and elevated corticotropin-releasing hormone (CRH) levels. This dysregulation reflects both trait-like vulnerability and state-dependent stress responses to suicidal crises. Elevated cortisol impairs prefrontal cortex function while enhancing amygdala reactivity, biasing cognitive and emotional processing toward threat-detection and away from adaptive coping. Early trauma and adverse childhood experiences become biologically "encoded" through epigenetic modifications (DNA methylation, histone acetylation) of genes regulating glucocorticoid receptors and FKBP5, perpetuating HPA axis sensitization and lifelong stress reactivity. This explains why childhood abuse is one of the most robust predictors of suicidal behavior—the developing brain's stress-response systems become fundamentally altered, creating a biological diathesis independent of current psychiatric symptoms.

• Prefrontal cortex dysfunction and impaired behavioral inhibition: The ventromedial prefrontal cortex (vmPFC) and dorsolateral prefrontal cortex (dlPFC) normally exert inhibitory control over limbic structures (amygdala, ventral striatum) and suppress prepotent but maladaptive responses. Neuroimaging studies consistently demonstrate reduced gray matter volume, reduced activation during executive function tasks, and impaired functional connectivity between prefrontal and limbic regions in suicidal individuals. Structurally, the anterior cingulate cortex shows reduced volume and altered white matter integrity in suicide completers. This prefrontal hypofunction creates a critical vulnerability: during acute stress or emotional dysregulation, individuals lose the neurobiological "brake" necessary to inhibit suicidal urges, particularly when combined with serotonergic hypofunction that reduces overall impulse control. The severity of prefrontal dysfunction correlates with behavioral lethality—those with more severe prefrontal abnormalities tend to use more violent methods and show higher intent-to-die. This also explains why impulsivity is a more powerful suicide risk factor than depression severity alone; depression is a mood symptom, but impulsivity reflects a trait-like neurobiological vulnerability.

• Genetic vulnerability and heritability: Twin studies estimate suicide attempt heritability at approximately 30-50%, with heritability of completed suicide even higher at 50-55%. However, suicide is not a heritable psychiatric disorder itself; rather, the heritable components reflect underlying vulnerabilities to psychiatric illness (depression, bipolar disorder, schizophrenia, borderline personality disorder) and temperamental traits (impulsivity, aggression, novelty-seeking). The serotonin transporter gene polymorphism (5-HTTLPR), the brain-derived neurotrophic factor (BDNF) val66met polymorphism, and variations in the monoamine oxidase A (MAOA) gene have all been implicated. Crucially, gene-by-environment interactions are more predictive than genetic variants alone: the low-activity MAOA variant predicts aggression and violence only in individuals with childhood maltreatment—in the absence of trauma, the genetic risk is not expressed. This underscores that genetic predisposition must interact with environmental factors to manifest as suicidal behavior.

• Inflammatory pathway activation and neuroinflammation: Emerging evidence demonstrates elevated pro-inflammatory cytokines (IL-6, TNF-α, IL-1β) in individuals with suicidal ideation and particularly in those who attempt suicide. Neuroinflammation activates microglial cells in the brain, promoting synaptic pruning and neuronal loss, particularly in the prefrontal cortex and anterior cingulate. The inflammatory cascade is triggered by chronic stress, psychiatric illness, early trauma, and may represent a final common pathway through which diverse risk factors converge. Elevated C-reactive protein (CRP) correlates with suicidal ideation severity independent of depression severity, suggesting inflammation as a partially independent biological mechanism. This has implications for treatment: NSAIDs and other anti-inflammatory approaches are being investigated as augmentation strategies for standard psychiatric treatments.

• Impaired decision-making and future discounting: The ventromedial prefrontal cortex integrates reward and punishment information to assign relative value to outcomes, a process called "temporal discounting." Suicidal individuals show dramatically altered temporal discounting—they heavily devalue future positive outcomes (relationships, achievements, experiences) while simultaneously overweighting immediate pain and distress. Neurobiologically, this reflects hypofunction of the vmPFC and striatal reward systems, reducing the motivational salience of life-affirming future outcomes. From a behavioral economics perspective, suicide becomes a "rational" decision when the present suffering is intense and future rewards are perceived as worthless—the decision-making apparatus is intact but operating with fundamentally altered value assignments. This explains why suicidal individuals often seem "rational" and thoughtful about their decision to die; they are not necessarily psychotic or incompetent, but their decision-making substrate has been altered by illness and distress.

• Psychiatric illness as the primary proximal risk factor: Major depressive disorder accounts for approximately 40-50% of suicides, bipolar disorder for 10-15%, schizophrenia for 5-10%, and substance use disorders for 20-25%, with significant overlap. The mechanism of depression-related suicide involves the core symptoms of hopelessness, anhedonia (loss of reward sensitivity), and concentration difficulties that impair problem-solving and social connection—protective factors are systematically eroded. In bipolar disorder, suicide risk is highest during mixed states (depressed mood with racing thoughts and agitation) rather than pure mania or depression; the combination creates intense dysphoria with preserved energy and goal-directedness to act on suicidal urges. Schizophrenia-related suicide is often driven by command hallucinations or delusional content (e.g., delusions of reference where the person believes they are specially destined to die), though approximately 50% of schizophrenia suicides occur in periods of relative remission, driven by demoralization from chronic disability and social isolation. Borderline personality disorder (BPD) has the highest suicide completion rate among psychiatric disorders (~10% lifetime risk), driven by the combination of affective instability, impulsivity, and chronic suicidality as a core feature; moreover, suicide in BPD may occur without severe depression, simply as an impulsive act during emotional dysregulation. Panic disorder, posttraumatic stress disorder (PTSD), and eating disorders (particularly anorexia nervosa) are also significant risk factors, often co-occurring with primary mood disorders. Substance use disorder is a critical risk factor both directly (through disinhibition and impaired judgment) and indirectly (through the depression and social consequences it causes); alcohol use is particularly associated with impulsive suicide attempts (hours to days from ideation to attempt), while opioid use disorder carries rising risk in the current epidemic.

• Impulsivity and behavioral disinhibition as trait vulnerabilities: Impulsivity is a dimensional trait that predicts suicide even independent of psychiatric diagnosis and mood state severity. Individuals with high trait impulsivity (measured by tests of response inhibition, delay discounting, and personality questionnaires like the Barratt Impulsiveness Scale) show faster progression from ideation to attempt—what researchers call a short "planning horizon." Aggressive and violent individuals are at particular risk; the combination of aggression and depression (rather than depression alone) dramatically increases suicide risk. This explains why suicide risk assessment must evaluate both current mood and trait characteristics: a person with moderate depression but very high impulsivity may be at higher acute risk than someone with severe depression but low impulsivity. The neurobiological basis involves orbitofrontal and ventromedial prefrontal hypofunction combined with serotonergic deficiency, creating a brain state optimized for behavioral disinhibition. Clinically, this means impulsive patients require more intensive monitoring and restriction of means because they may transition from suicidal thought to action in hours rather than days, without warning.

• Negative life events and acute stressors as precipitants: Suicide attempts cluster following specific life stressors: recent psychiatric hospitalization, job loss, legal trouble, relationship dissolution, financial crisis, social rejection, and failures in achievement. The psychological mechanism involves cognitive models of suicide where distal risk factors (psychiatric illness, trait impulsivity, childhood trauma) combine with proximal stressors that trigger acute emotional dysregulation and crisis perception. A person with chronic depression might develop suicidal ideation following a romantic rejection, or someone with personality disorder might attempt following a perceived social slight. These stressors activate the anterior insula (involved in distress sensitivity), amplify amygdala reactivity, and further suppress prefrontal function. Access to means during high-stress periods is critical—restriction of access to lethal means (guns, medications, pesticides) during acute crisis periods reduces suicide completion rates. In the United States, firearm access is a major modifiable risk factor; individuals with suicidal ideation living in homes with firearms are at dramatically increased risk of completed suicide.

• Chronic medical illness and pain as underrecognized risk factors: Chronic pain, cancer, terminal illness, traumatic brain injury, multiple sclerosis, and spinal cord injury all carry significantly elevated suicide risk. The mechanism involves both the psychological impact of disability and the direct effect of chronic inflammatory states on the brain. Physician-assisted suicide remains legal in a limited number of jurisdictions and may occur in these populations; clinicians must distinguish between rational requests for aid-in-dying (which may be legal) and suicidality arising from depression (which requires psychiatric intervention). Chronic pain directly impairs serotonergic function and is associated with altered HPA axis activity; individuals with chronic pain have both a biological and psychological substrate for suicidality. Cancer-related suicide is particularly elevated in patients diagnosed shortly before suicide (within 6 months to 1 year), suggesting that acute threat perception drives risk; psychosocial support and psychiatric intervention during initial diagnosis may reduce suicide in this population.

• Demographic risk factors and social determinants: Men are 3-4 times more likely to die by suicide than women (in most Western countries), a difference driven largely by method lethality—men are more likely to use firearms and hanging, while women more often attempt with medications. Age is bimodal: adolescence and young adulthood represent one peak (driven by impulsivity, access to means, and the emergence of psychiatric illness), and older adulthood (especially men >75 years) represents another peak (driven by medical illness, social isolation, and chronic pain). Caucasian, non-Hispanic populations have elevated suicide rates in the United States, particularly men, though this varies regionally and has changed over time. American Indian and Alaska Native populations have suicide rates 3-5 times the U.S. average, driven by historical trauma, socioeconomic disparities, substance abuse, and limited mental health access. Lesbian, gay, bisexual, transgender, and questioning (LGBTQ+) individuals have 4-6 times elevated suicide risk, particularly adolescents, driven by minority stress, discrimination, and family rejection. Occupational groups at elevated risk include farmers (access to lethal means including pesticides and firearms), healthcare workers (access to medications), military personnel (combination of risk factors including trauma exposure, substance use, and access to firearms), and incarcerated individuals (confined environment with limited coping resources and access to means).

• Childhood trauma and adverse experiences as foundational vulnerability: Early abuse, neglect, and witness to violence create both direct neural consequences (prefrontal hypofunction, amygdala hyperreactivity, altered HPA axis) and psychological sequelae (insecure attachment, distorted beliefs about self and others, difficulty with emotion regulation). The dose-response relationship is clear: individuals with more adverse childhood experiences (ACEs) show progressively higher suicide risk even decades later. The mechanism involves epigenetic modifications that persistently alter glucocorticoid receptor expression and HPA axis sensitivity; this is not simply psychological learning but involves lasting changes to gene regulation. Childhood trauma increases suicide risk both directly (through neural changes) and indirectly (through increased vulnerability to psychiatric illness). Moreover, specific types of trauma carry particular risk: sexual abuse and childhood sexual assault carry especially high suicide risk, possibly through combined effects on shame, self-esteem, and interpersonal relationships.

• Social isolation and disconnection as modifiable risk factors: Chronic loneliness, social isolation, weak social networks, and low social integration predict suicide independent of psychiatric diagnosis. The Interpersonal Theory of Suicide (Joiner) proposes that two critical factors are necessary for suicide: thwarted belongingness (feeling disconnected from valued groups/persons) and perceived burdensomeness (feeling like a burden to others). Individuals may have suicidal ideation but not attempt unless both factors are present—this theory explains why social connection and strengthening relationships are powerful protective interventions. The biological correlates of isolation involve reduced oxytocin signaling, impaired vagal tone (reduced parasympathetic activation), and dysregulation of the social neurocircuitry. Rural populations and rural older males are at particularly high risk due to social isolation and reduced mental health access.

• Access to means and method planning: The availability of lethal means is a critical modifiable risk factor. Individuals with access to firearms are significantly more likely to die by suicide; moreover, the lethality of the method chosen predicts outcome. Firearms are fatal in >90% of attempts, hanging in >60%, carbon monoxide in ~50%, whereas overdose on medications is fatal in <5%. Men use more lethal means than women, which is a major reason for higher male completion rates. Restricting access to means (firearm safety counseling and storage, asking about safe medication storage, restricting access to pesticides in at-risk agricultural populations) is one of the few suicide prevention interventions with strong evidence for preventing completion, not just attempts. Clinically, asking about firearm access and counseling on safe storage is a high-value intervention.

• Suicidal ideation (SI) as the cardinal symptom with variable manifestations: Passive suicidal ideation involves the wish to be dead or that something would happen to cause death, without active planning or intent to act—for example, wishing not to wake up from sleep or that a car accident would happen. Passive SI is more common and generally carries lower acute risk, though it should not be dismissed as "safe." **

Step 1 — Screening (initial "test")

• Validated screening instruments: The Joint Commission National Patient Safety Goal 15.01.01 requires screening all patients whose primary reason for care is a behavioral health condition using a validated tool. Common instruments are the Ask Suicide-Screening Questions (ASQ), the Columbia-Suicide Severity Rating Scale (C-SSRS) screener, and item 9 of the PHQ-9 (thoughts of being better off dead or of self-harm), which is positive at any response above "not at all."
• Screening context: The USPSTF recommends depression screening in adults, including pregnant and postpartum persons, and in adolescents; for stand-alone suicide-risk screening in asymptomatic populations the USPSTF has issued an insufficient-evidence (I) statement. A positive screen mandates evaluation, never simply repeat testing.

Step 2 — Confirmatory structured assessment (gold standard)

• Direct clinical interview covering the ideation-to-action spectrum: passive wish to die → active ideation → method → plan, intent, preparatory acts, rehearsal, and access to means (especially firearms). The C-SSRS grades ideation 1–5 (1 = wish to be dead; 5 = active ideation with specific plan and intent) and separately codes behaviors (aborted, interrupted, actual attempt, preparatory acts).
• Corroborating history: prior attempts and their lethality/rescuability, psychiatric diagnosis, substance use, hopelessness, insomnia, agitation, recent discharge, and protective factors.

Step 3 — Medical evaluation after an attempt

• Toxicology and metabolic panel: serum acetaminophen level at 4 hours post-ingestion plotted on the Rumack-Matthew nomogram, salicylate level, ethanol, glucose, electrolytes, and pregnancy testing.
• ECG: in suspected tricyclic overdose, QRS >100 ms predicts seizure and >160 ms predicts ventricular arrhythmia.

Immediate stabilization

• Environmental safety first: continuous 1:1 observation, removal of belongings and ligature points, and search for medications or weapons. The Joint Commission requires a ligature-resistant environment for patients at high risk in psychiatric units.
• Medical stabilization of the attempt precedes psychiatric disposition: ABCs, then antidote-directed care — N-acetylcysteine for acetaminophen, naloxone for opioids, sodium bicarbonate for tricyclic-induced QRS widening, flumazenil generally avoided (seizure risk in mixed ingestion/chronic benzodiazepine use).
• Disposition: voluntary admission is preferred; if the patient has a mental illness and is a danger to self and refuses, involuntary hold/civil commitment under state statute is indicated. Refusal of care in this setting does not require the patient to be globally incompetent, only to meet statutory dangerousness criteria.

Core interventions for all at-risk patients (APA guideline; Zero Suicide model)

• Safety planning: the Stanley-Brown Safety Planning Intervention — warning signs, internal coping, contacts, crisis line (988), and means restriction. "No-suicide contracts" are not evidence-based and should not be used.
• Lethal means counseling: firearm storage off-site or locked; limiting pill quantity dispensed.

Disease-directed pharmacotherapy

• SSRIs (e.g., sertraline) are first-line for the underlying depressive or anxiety disorder; effect on suicidality follows symptom improvement over weeks.
• Lithium has the strongest evidence for reducing suicide in bipolar disorder and recurrent depression — but it is itself lethal in overdose, so quantity must be limited.
• Clozapine is FDA-approved to reduce recurrent suicidal behavior in schizophrenia and schizoaffective disorder.
• Esketamine (intranasal, with an oral antidepressant) is FDA-approved for depressive symptoms with acute suicidal ideation or behavior, given under REMS with post-dose monitoring.

Escalation

• Electroconvulsive therapy for severe depression with imminent suicidality, catatonia, psychotic depression, or refusal to eat/drink.
• Psychotherapies with attempt-reduction evidence: CBT for suicide prevention and dialectical behavior therapy (first-line for borderline personality disorder).

Complications of the disorder

• Completed suicide — the terminal outcome; a prior attempt is the single strongest predictor, and risk is concentrated in the days to weeks after psychiatric hospitalization or ED discharge, when supervision drops but hopelessness persists. Emergency.
• Repeat attempt with escalating lethality: each attempt reinforces acquired capability (habituation to fear of death and pain), so subsequent attempts trend toward more lethal methods.
• Organ injury from the attempt itself: acetaminophen-induced fulminant hepatic failure (rising transaminases then INR and encephalopathy), anoxic brain injury and cervical/airway injury after hanging, rhabdomyolysis and compartment syndrome from prolonged down-time (dark urine, markedly elevated CK, rising creatinine), and aspiration pneumonitis in the obtunded overdose patient. All emergencies.
• Cardiotoxicity in tricyclic overdose: sodium-channel blockade widens QRS and produces a terminal R wave in aVR, progressing to ventricular arrhythmia and seizure. Emergency.

Complications of treatment

• Antidepressant-associated activation: the FDA boxed warning applies to patients under age 25; psychomotor retardation may lift before mood does ("energy before hope"), transiently enabling action on pre-existing ideation. Signals are new agitation, akathisia, and insomnia in the first weeks.
• Antidepressant-induced mania or mixed state in undiagnosed bipolar disorder — mixed states carry the highest suicide risk of any mood state.
• Serotonin syndrome with overdose or combination therapy: clonus, hyperreflexia, hyperthermia, autonomic instability. Emergency.
• Lithium toxicity: narrow therapeutic index; tremor, ataxia, confusion, and seizure, precipitated by dehydration, NSAIDs, thiazides, or ACE inhibitors. Emergency at high levels.
• Clozapine: agranulocytosis (ANC monitoring under REMS), myocarditis in the first weeks (fever, chest pain, eosinophilia, troponin rise), seizures, and severe constipation/ileus. Emergencies.
• ECT: transient retrograde/anterograde amnesia and post-ictal confusion; esketamine: dissociation and blood-pressure elevation requiring supervised monitoring.
• Iatrogenic harm from coercion: involuntary hospitalization can rupture the therapeutic alliance and deter future disclosure — an argument for the least restrictive effective setting.

• Prior suicide attempt is the strongest single predictor of completed suicide; hopelessness predicts eventual suicide better than depression severity score does. Examiners test hopelessness over sadness.
• Asking directly about suicide does not plant the idea — this is the most commonly tested distractor. The single best next step when a patient hints at wanting to die is always to ask explicitly about ideation, plan, intent, and access to means.
• The "gender paradox": women attempt more often, men complete 3–4× more often, driven by method lethality (firearms, hanging). A firearm in the home is the highest-yield modifiable risk factor — ask about it and counsel on removal or locked storage.
• Two agents with disease-specific anti-suicide evidence: lithium (bipolar disorder, recurrent depression) and clozapine (FDA-approved to reduce recurrent suicidal behavior in schizophrenia/schizoaffective disorder). SSRIs treat the underlying illness but are not the "anti-suicide drug" answer.
• Two highest-risk windows: the first weeks after starting an antidepressant (psychomotor activation returns before mood improves) and the first weeks after psychiatric discharge. A stem describing a depressed patient who "suddenly seems calm and resolved" or is newly energized is describing danger, not recovery.
• Safety planning, not a "no-harm contract." The Stanley-Brown Safety Planning Intervention plus lethal means restriction is the correct answer; contracts for safety have no evidence and are the classic wrong choice.
• Confidentiality yields to safety: a patient with active ideation, plan, and intent who refuses admission is held involuntarily under state civil-commitment law. Capacity to refuse other medical care does not override dangerousness criteria.
• Common distractor to reject: using the SAD PERSONS mnemonic score to decide disposition. Board answers favor structured instruments such as the C-SSRS or ASQ combined with clinical risk formulation, per the APA guideline and Joint Commission NPSG 15.01.01.